- Last sale
- Nov 12, 2026 · -5.57%
- Market cap
- $1.71B
- 65.41M shares
- Filings
- 636
Q3 2026+404.5% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−34.2% FY25 yoy
- $1.71B
- —
- 60.7×
- 4.9×
- -12.60%
- —
Twelve months to Sep 30, 2026 · derived
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $184,420,000 | reported | |
| FY 2024 | 2024-12-31 | $36,555,000 | reported | |
| FY 2023 | 2023-12-31 | $8,780,000 | reported | |
| FY 2022 | 2022-12-31 | $12,405,000 | reported |
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR